These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 19432557)

  • 1. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
    Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
    Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The selectivity of inhibitors of protein kinase CK2: an update.
    Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
    Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Selectivity of CK2 Inhibitor Quinalizarin: A Reevaluation.
    Cozza G; Venerando A; Sarno S; Pinna LA
    Biomed Res Int; 2015; 2015():734127. PubMed ID: 26558278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
    Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
    Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases.
    Cozza G; Sarno S; Ruzzene M; Girardi C; Orzeszko A; Kazimierczuk Z; Zagotto G; Bonaiuto E; Di Paolo ML; Pinna LA
    Biochim Biophys Acta; 2013 Jul; 1834(7):1402-9. PubMed ID: 23360763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and exploitation of CK2 inhibitors.
    Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
    Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of a phosphoproteome readily altered by the protein kinase CK2 inhibitor quinalizarin in HEK-293T cells.
    Franchin C; Cesaro L; Salvi M; Millioni R; Iori E; Cifani P; James P; Arrigoni G; Pinna L
    Biochim Biophys Acta; 2015 Jun; 1854(6):609-23. PubMed ID: 25278378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
    Leung KK; Shilton BH
    Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomics perturbations promoted by the protein kinase CK2 inhibitor quinalizarin.
    Franchin C; Salvi M; Arrigoni G; Pinna LA
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1676-86. PubMed ID: 25882195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATP site-directed inhibitors of protein kinase CK2: an update.
    Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
    Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A.
    Sarno S; Mazzorana M; Traynor R; Ruzzene M; Cozza G; Pagano MA; Meggio F; Zagotto G; Battistutta R; Pinna LA
    Cell Mol Life Sci; 2012 Feb; 69(3):449-60. PubMed ID: 21720886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole.
    Pagano MA; Andrzejewska M; Ruzzene M; Sarno S; Cesaro L; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Pinna LA
    J Med Chem; 2004 Dec; 47(25):6239-47. PubMed ID: 15566294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole.
    Battistutta R; Mazzorana M; Sarno S; Kazimierczuk Z; Zanotti G; Pinna LA
    Chem Biol; 2005 Nov; 12(11):1211-9. PubMed ID: 16298300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological properties and structural study of new aminoalkyl derivatives of benzimidazole and benzotriazole, dual inhibitors of CK2 and PIM1 kinases.
    Chojnacki K; Wińska P; Wielechowska M; Łukowska-Chojnacka E; Tölzer C; Niefind K; Bretner M
    Bioorg Chem; 2018 Oct; 80():266-275. PubMed ID: 29966873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
    Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
    Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward selective CK2alpha and CK2alpha' inhibitors: Development of a novel whole-cell kinase assay by Autodisplay of catalytic CK2alpha'.
    Bollacke A; Nienberg C; Borgne ML; Jose J
    J Pharm Biomed Anal; 2016 Mar; 121():253-260. PubMed ID: 26786382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
    Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
    Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2.
    Golub AG; Yakovenko OY; Prykhod'ko AO; Lukashov SS; Bdzhola VG; Yarmoluk SM
    Biochim Biophys Acta; 2008 Jan; 1784(1):143-9. PubMed ID: 18021749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2').
    Sarno S; Reddy H; Meggio F; Ruzzene M; Davies SP; Donella-Deana A; Shugar D; Pinna LA
    FEBS Lett; 2001 May; 496(1):44-8. PubMed ID: 11343704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel class of selective CK2 inhibitors targeting its open hinge conformation.
    Dalle Vedove A; Zonta F; Zanforlin E; Demitri N; Ribaudo G; Cazzanelli G; Ongaro A; Sarno S; Zagotto G; Battistutta R; Ruzzene M; Lolli G
    Eur J Med Chem; 2020 Jun; 195():112267. PubMed ID: 32283296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.